Article PDF first page preview

First page of Do transdermal administration of α1 and α2 adrenergic receptor antagonists modulate sweating in exercising young females in the heat?

Introduction Adrenergic modulation of sweating remains equivocal in females. We investigated whether α1- and α2-adrenergic receptors can modulate sweating during active heat stress in healthy female participants. Methods Thirty young adults (15 females) cycled at 50% peak oxygen uptake for 30 minutes at 32°C and 40% relative humidity. Sweat rates (ventilated capsule technique) on both forearms were assessed following pre-treatment with terazosin (α1-adrenergic receptor antagonist), rauwolscine (α2-antagonist), or control (NaCl) using transdermal iontophoresis procedure. The efficacy of α1-blockade was confirmed post-exercise with phenylephrine (α1-adrenergic agonist)-induced sweating, while α2-antagonist efficacy was verified in a separate follow-up study assessing clonidine (α2-agonist)-induced cutaneous vasoconstriction. Results Participants sweated by 0.32 ± 0.13 and 0.54 ± 0.26 mg cm-2 min-1 at the end of exercise for males and females, respectively. Neither terazosin nor rauwolscine affected sweating during exercise in males (P ≥ 0.125, interaction and treatment effect) or females (P ≥ 0.277) as compared to control sites. However, the reduction in sweat rate at the terazosin-treated site was negatively correlated with sweat rate at control sites in both sexes (all P ≤ 0.050, r ≤ 0.514), while no such correlation was observed for rauwolscine. Successful α1-blockade was confirmed by attenuated phenylephrine-induced sweating during post-exercise (P ≤ 0.025). Rauwolscine effectively abolished clonidine-induced cutaneous vasoconstriction in a follow-up study, verifying successful transdermal delivery. Conclusion The α₁- and α₂-adrenergic receptors do not alter sweating during moderate-intensity exercise in males and females, at least among individuals with relatively low sweat production.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.